Devonian Heath Group Inc. to participate in Renmark’s No-Deal Virtual Roadshow Series in Los Angeles, USA today July 20, 2021


CITY OF QUEBEC, July 20, 2021– (BUSINESS WIRE) – Devonian Health Group Inc. (“Devonian“or the”society“) (TSXv: GSD), a clinical-stage botanical pharmaceutical company focused on developing a unique portfolio of botanical pharmaceutical and cosmeceuticals, today announced that it will participate in Renmark Financial Communications Inc.’s Virtual Non-Deal Roadshow series at Renmark Financial Communications Inc. Los Angeles (US) to discuss their latest corporate presentation today, July 20 at 1:00 p.m. PST. Devonian Health Group Inc. invites stakeholders, investors and other individual subscribers to register and attend this event live.

The presentation will feature Sybil Dahan, President of Devonian’s Commercial Division. Topics to cover will include the latest business presentation followed by a live Q&A. Those interested in participating in this event will need to register using the link below. As a reminder, registration for the live event may be limited but access to the replay after the event will be on the Company’s Investor website.


To ensure smooth connectivity, please access this link using the latest version of Google Chrome.

About the Devonian

Devonian Health Group Inc. is an advanced stage botanical pharmaceutical company with novel therapeutic approaches to target unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of autoimmune inflammatory diseases including, but not limited to ulcerative colitis and atopic dermatitis. . Based on a foundation of over 15 years of research, Devonian’s goal is further supported by a set of US-FDA regulatory guidelines promoting a more efficient drug development pathway for prescription botanical pharmaceuticals over those traditional prescription drugs. Devonian is also involved in the development of high value cosmeceuticals using the same proprietary approach used with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Quebec, Canada, where it has a state-of-the-art extraction facility with full “seed to pill” traceability. Acquired in 2018, Altius Healthcare Inc., its marketing partner, offers opportunities for further diversification and growth potential. Devonian is listed on the TSXV (TSXv: GSD).

For more information, visit

Forward-looking statements

This press release contains forward-looking statements about Devonian’s objectives, strategies and business that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets in which we operate and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. These risks and assumptions include, but are not limited to, Devonian’s ability to successfully develop, manufacture and market value-added pharmaceutical and cosmeceuticals, the availability of funds and resources to pursue R&D projects, the completion successful and on schedule with clinical studies, Devonian’s ability to take advantage of business opportunities in the pharmaceutical and cosmeceutical industries, uncertainties in the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to differ materially from our current expectations in Devonian’s prospectus dated April, 2017 under the heading “Risk factors” related to the activities of Devonian. Therefore, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement, even if new information becomes available, as a result of future events or for any other reason, unless applicable securities laws and regulations do not apply. ‘demand.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

See the source version on


Renmark Financial Communications Inc.
Scott Logan: [email protected]
Phone. : (416) 644-2020 or (212) 812-7680

Source link

Leave A Reply

Your email address will not be published.